- ホーム
- > 洋書
- > 英文書
- > Science / Mathematics
Full Description
Cutting-edge Nanocarrier-based Strategies in the Management of Leukaemia addresses the growing importance of nanocarriers in leukaemia treatment. It explores advancements in nanotechnology, highlighting therapies like siRNA, miRNA, and gene therapy that improve patient outcomes. This book fills a critical gap in current literature, serving as a valuable resource for researchers, clinicians, and students. This book begins with an introduction to leukemia, covering its epidemiology and risk factors. It then delves into innovative therapies and the use of various nanocarriers such as polymeric nanoparticles, liposomes, dendrimers, and hydrogels. Additionally, it discusses precision medicine, AI in leukaemia care, and strategies to overcome treatment resistance, enriched with tables, figures, and images. Healthcare providers, including physicians, immunologists, oncologists, and pharmacists, will find this book invaluable. It educates on cutting-edge therapies and offers practical insights into personalized patient care, making it essential for those involved in leukaemia management.
Contents
1. Introduction
2. siRNA and miRNA therapies for leukaemia
3. Gene therapy for leukaemia
4. Exploring Polymeric nanoparticles in leukaemia management
5. Magnetic Nanoparticles in Leukemia Therapy: Advancements and Future Directions
6. Mesoporous Silica Nanoparticles: A Novel Approach in Targeted Leukemia Therapy
7. Targeted Leukemia Therapy with Solid Lipid Nanoparticles: Potential and Progress
8. The Role of Exosomes in Leukemia Treatment: Advancements in Biomarker Discovery and Drug Delivery
9. Nanoemulsion-Based Drug Delivery in Leukemia: Potential and Progress in Therapeutic Applications
10. Advances in Leukemia Treatment using Micelles and Dendrimers
11. Revolutionizing Leukemia Therapy with Liposomes and Niosomes: Targeted Delivery and Improved Efficacy
12. Biological and immunological aspects of nanocarriers and nano-vaccines
13. Leveraging AI and machine learning for prostate cancer management 14. Role of DNA Origami and mRNA/siRNA nanocarriers in prostate cancer
